NAFTIDROFURYL IN COMPARISON TO ALPROSTADIL IN PERIPHERAL ARTERIAL OCCLUSIVE DISEASE STAGE-III AND STAGE-IV

A prospective, open, randomised study was performed in 30 patients with peripheral arterial occlusive disease in stade III and IV comparing either 400 mg Naftidrofuryl or 40 mug Alprostadil i. v. twice daily during 21 days. Assessment of treatment success by response of the main symptom (either rest pain or necrosis) resulted in a responder rate of 11 patients in each treatment group. Complete recovery of rest pain appeared in 7 of 13 rest pain patients under Naftidrofuryl and 9 of 14 Alprostadil patients. Complete healing of necrosis succeeded in 1 Naftidrofuryl patient. A partial success was found in 6 Naftidrofuryl and 4 Alprostadil patients. Thus a comparison between both active compounds does not show any relevant difference of therapeutical benefit under the defined treatment conditions. No side effects occurred causing withdrawal of treatment. A cost-benefit-analysis results in a considerable advantage in the use of Naftidrofuryl.